NCT06862284View on ClinicalTrials.gov

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

August 31, 2027

Conditions
Primary Sjögren's Syndrome (pSS)
Interventions
DRUG

Upadacitinib (ABT-494)

Upadacitinib 15mg Qd for 52 weeks

DRUG

Hydroxychloroquine (HCQ)

Hydroxychloroquine 200mg Bid for 52 weeks

Trial Locations (1)

100044

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER